The Law Office of Vincent Wong is investigating the Board of Directors of Penwest Pharmaceuticals Co. (NasdaqGM: PPCO) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Endo Pharmaceuticals Holdings Inc. (NasdaqGS: ENDP). Under the terms of the deal, Penwest shareholders will receive $5.00 in cash per share for a total transaction value of approximately $168 million.

The investigation concerns whether the Penwest Board of Directors breached their fiduciary duties to Penwest stockholders by failing to adequately shop the Company before entering into this transaction and whether Endo is underpaying for Penwest shares.

If you own common stock in Penwest and wish to obtain additional information about this investigation and what is being done to advance the shareholders’ interests, please contact Vincent Wong, Esq. directly, via email at vw@wongesq.com, by telephone at 212.584.2740, or visit http://www.wongesq.com/penwest-ppco.html.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

Penwest (NASDAQ:PPCO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Penwest.
Penwest (NASDAQ:PPCO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Penwest.